Predictive biomarkers for systemic therapy of hepatocellular carcinoma

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149(4):778–789.
   Web of Science ®Google Scholar
• Golabi P, Fazel S, Otgonsuren M, et al. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore). 2017;96(9):e5904.
   PubMed Web of Science ®Google Scholar
• Fitzmorris P, Shoreibah M, Anand BS, et al. Management of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2015;141(5):861–876.
   PubMed Web of Science ®Google Scholar
• Ikeda K. Recent advances in medical management of hepatocellular carcinoma. Hepatol Res. 2019;49(1):14–32.
   PubMed Web of Science ®Google Scholar
• Buschauer S, Koch A, Wiggermann P, et al. Hepatocellular carcinoma cells surviving doxorubicin treatment exhibit increased migratory potential and resistance to doxorubicin re-treatment in vitro. Oncol Lett. 2018;15(4):4635–4640.
   PubMed Web of Science ®Google Scholar
• Kudo M, Ueshima K, and Yokosuka O, et al. SILIUS study group. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3(6):424–432.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, and Mazzaferro V, et al. Sharp investigators study group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173.
   PubMed Web of Science ®Google Scholar
• Thillai K, Srikandarajah K, Ross P. Regorafenib as treatment for patients with advanced hepatocellular cancer. Future Oncol. 2017;13(25):2223–2232.
   PubMed Web of Science ®Google Scholar
• Kudo M. Targeted and immune therapies for hepatocellular carcinoma: predictions for 2019 and beyond. World J Gastroenterol. 2019;25(7):789–807.
   PubMed Web of Science ®Google Scholar
• Neureiter D, Stintzing S, Kiesslich T, et al. Hepatocellular carcinoma: therapeutic advances in signaling, epigenetic and immune targets. World J Gastroenterol. 2019;25(25):3136–3150.
   PubMed Web of Science ®Google Scholar
• Galicia-Moreno M, Silva-Gomez JA, Lucano-Landeros S, et al. Liver cancer: therapeutic challenges and the importance of experimental models. Can J Gastroenterol Hepatol. 2021;2021:8837811.
   PubMed Web of Science ®Google Scholar
• De Mattia E, Cecchin E, Guardascione M, et al. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. World J Gastroenterol. 2019;25(29):3870–3896.
   PubMed Web of Science ®Google Scholar
• Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010;5(6):463–466.
   PubMed Web of Science ®Google Scholar
• Oldenhuis CN, Oosting SF, Gietema JA, et al. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer. 2008;44(7):946–953.
   PubMed Web of Science ®Google Scholar
• Rizk EM, Gartrell RD, Barker LW, et al. Prognostic and predictive immunohistochemistry-based biomarkers in cancer and immunotherapy. Hematol Oncol Clin North Am. 2019;33(2):291–299.
   PubMed Web of Science ®Google Scholar
• Sechidis K, Papangelou K, Metcalfe PD, et al. Distinguishing prognostic and predictive biomarkers: an information theoretic approach. Bioinformatics. 2018;34(19):3365–3376.
   PubMed Web of Science ®Google Scholar
• Sechidis K, Kormaksson M, Ohlssen D. Using knockoffs for controlled predictive biomarker identification. Stat Med. 2021. DOI:https://doi.org/10.1002/sim.9134
   Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology. 2018;68(2):723–750.
   PubMed Web of Science ®Google Scholar
• Terentiev AA, Moldogazieva NT. Alpha-fetoprotein: a renaissance. Tumor Biol. 2013;34(4):2075–2091.
   PubMedGoogle Scholar
• MizejewskiGJ. Does alpha-fetoprotein contribute to the mortality and morbidity of human hepatocellular carcinoma? A commentary. J Hepatocell Carcinoma. 2016;3:37–40.
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Getz G, and Korbel JO, et al.; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature. 2020;578(7793):82–93.
   PubMed Web of Science ®Google Scholar
• Zhang T, Yin M, Wang L, et al. Diagnostic performance of blood-based liquid biopsies in hepatocellular carcinoma: a protocol for systematic review and meta-analysis. Medicine (Baltimore). 2020;99(41):e22594.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both RAF and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7(10):3129–3140.
   PubMed Web of Science ®Google Scholar
• Cervello M, Bachvarov D, Lampiasi N, et al. Molecular mechanisms of sorafenib action in liver cancer cells. Cell Cycle. 2012;11(15):2843–2855.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Peña CE, Lathia CD, et al., SHARP Investigators Study Group. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012;18(8):2290–2300.
   PubMed Web of Science ®Google Scholar
• Tsuchiya K, Asahina Y, Matsuda S, et al. Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. Cancer. 2014;120(2):229–237.
   PubMed Web of Science ®Google Scholar
• Lee JH, Chung YH, Kim JA, et al. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer. 2013;119(1):136–142.
   PubMed Web of Science ®Google Scholar
• Wang P, Tan G, Zhu M, et al. Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2018;12(1):1–8.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Lamarca A. Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival. Expert Rev Gastroenterol Hepatol. 2017;11(1):75–83.
   PubMed Web of Science ®Google Scholar
• Granito A, Marinelli S, and Negrini G, et al. Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib. Therap Adv Gastroenterol. 2016;9(2):240–249.
   PubMed Web of Science ®Google Scholar
• Marisi G, Cucchetti A, and Ulivi P, et al. Ten years of sorafenib in hepatocellular carcinoma: are there any predictive and/or prognostic markers? World J Gastroenterol. 2018;24(36):4152–4163.
   PubMed Web of Science ®Google Scholar
• Edeline J, Blanc JF, Campillo-Gimenez B, et al. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: a new application for the hepatoma arterial embolisation prognostic score. Eur J Cancer. 2017;86:135–142.
   PubMed Web of Science ®Google Scholar
• Labeur TA, Berhane S, and Edeline J, et al. Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib. Liver Int. 2020;40(1):215–228.
   PubMed Web of Science ®Google Scholar
• Sansone V, Tovoli F, Casadei-Gardini A, et al. Comparison of prognostic scores in patients with hepatocellular carcinoma treated with sorafenib. Clin Transl Gastroenterol. 2021;12(1):e00286.
   PubMed Web of Science ®Google Scholar
• Kuzuya T, Asahina Y, Tsuchiya K, et al. Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology. 2011;81(3–4):251–258.
   PubMed Web of Science ®Google Scholar
• Kawaoka T, Aikata H, Murakami E, et al. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced hepatocellular carcinoma patients treated with sorafenib. Oncology. 2012;83(4):192–200.
   PubMed Web of Science ®Google Scholar
• Personeni N, Bozzarelli S, Pressiani T, et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2012;57(1):101–107.
   PubMed Web of Science ®Google Scholar
• He C, Peng W, Liu X, et al. Post-treatment alpha-fetoprotein response predicts prognosis of patients with hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore). 2019;98(31):e16557.
   PubMed Web of Science ®Google Scholar
• Nakazawa T, Hidaka H, Takada J, et al. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol. 2013;25(6):683–689.
   PubMed Web of Science ®Google Scholar
• Zhu YJ, Zheng B, Wang HY, et al. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 2017;38(5):614–622.
   PubMed Web of Science ®Google Scholar
• Pang L, Xu L, Yuan C, et al. Activation of EGFR-KLF4 positive feedback loop results in acquired resistance to sorafenib in hepatocellular carcinoma. Mol Carcinog. 2019;58(11):2118–2126.
   PubMed Web of Science ®Google Scholar
• Han P, Li H, Jiang X, et al. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells. Mol Oncol. 2017;11(3):320–334.
   PubMed Web of Science ®Google Scholar
• Shao W, Zhu W, and Lin J, et al. Liver X receptor agonism sensitizes a subset of hepatocellular carcinoma to sorafenib by dual-inhibiting MET and EGFR. Neoplasia. 2020;22(1):1–9.
   PubMed Web of Science ®Google Scholar
• Cui SX, Shi WN, Song ZY, et al. Des-gamma-carboxy prothrombin antagonizes the effects of sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways. Oncotarget. 2016;7(24):36767–36782.
   PubMedGoogle Scholar
• Yamazaki S, Takayama T, Kurokawa T, et al. Next-generation des-r-carboxy prothrombin for immunohistochemical assessment of vascular invasion by hepatocellular carcinoma. BMC Surg. 2020;20(1):201.
   PubMed Web of Science ®Google Scholar
• Miyahara K, Nouso K, Morimoto Y, et al. Okayama liver cancer group. evaluation of the effect of sorafenib using serum NX-des-γ-carboxyprothrombin in patients with hepatocellular carcinoma. Hepatol Res. 2013;43(10):1064–1070.
   PubMed Web of Science ®Google Scholar
• Sumi A, Akiba J, and Ogasawara S, et al. Des-y-carbioxyprothrombin (DCP) and NX-DCP expressions and their relationship with clinicopathological features in hepatocellular carcinoma. PLoS One. 2015;10(3):e0118452.
   PubMed Web of Science ®Google Scholar
• Jo H, Park Y, Kim T, et al. Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells. BMC Cancer. 2020;20(1):332.
   PubMed Web of Science ®Google Scholar
• Tao N-N, Zhou H-Z, and Tang H, et al. Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway. Oncotarget. 2016;7(31):50117–50130.
   PubMedGoogle Scholar
• Feng YH, Tung CL, Su YC, et al. Proteomic profile of sorafenib resistance in hepatocellular carcinoma; GRP78 expression is associated with inferior response to sorafenib. Cancer Genomics Proteomics. 2019;16(6):569–576.
   PubMed Web of Science ®Google Scholar
• Giannelli G, Koudelkova P, Dituri F, et al. Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol. 2016;65(4):798–808.
   PubMed Web of Science ®Google Scholar
• Dong J, Zhai B, Sun W, et al. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells. PLoS One. 2017;12(9):e0185088.
   PubMed Web of Science ®Google Scholar
• Wang B, Zhao Q, Zhang Y, et al. Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy. J Exp Clin Cancer Res. 2021;40(1):24.
   PubMed Web of Science ®Google Scholar
• Busche S, John K, Wandrer F, et al. BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment. Cell Death Dis. 2021;12(8):736.
   PubMed Web of Science ®Google Scholar
• El Shorbagy S, abu Taleb F, HA L, et al. Prognostic significance of VEGF and HIF-1α in hepatocellular carcinoma patients receiving sorafenib versus metformin sorafenib combination. J Gastrointest Cancer. 2021;52(1):269–279.
   PubMed Web of Science ®Google Scholar
• Godin C, Bodeau S, Saidak Z, et al. Early decrease in serum amphiregulin or vascular endothelial growth factor levels predicts sorafenib efficacy in hepatocellular carcinoma. Oncol Rep. 2019;41(3):2041–2050.
   PubMed Web of Science ®Google Scholar
• Goyal L, Zheng H, Abrams TA, et al. A phase II and biomarker study of sorafenib combined with modified FOLFOX in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2019;25(1):80–89.
   PubMed Web of Science ®Google Scholar
• Woo HG, Kim YJ. Multiplatform genomic roadmap of hepatocellular carcinoma: a matter of molecular heterogeneity. Hepatology. 2018;68(5):2029–2032.
   PubMed Web of Science ®Google Scholar
• Lin DC, Mayakonda A, and Dinh HQ, et al. Genomic and epigenomic heterogeneity of hepatocellular carcinoma. Cancer Res. 2017;77(9):2255–2265.
   PubMed Web of Science ®Google Scholar
• Schulze K, Imbeaud S, Letouzé E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47(5):505–511.
   PubMed Web of Science ®Google Scholar
• Kwon JH, Lee N, Park JY, et al. Actionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinoma. PLoS One. 2013;8(6):e64260.
   PubMed Web of Science ®Google Scholar
• Kim CM, Hwang S, Keam B, et al. Gene signature for sorafenib susceptibility in hepatocellular carcinoma: different approach with a predictive biomarker. Liver Cancer. 2020;9(2):182–192.
   PubMed Web of Science ®Google Scholar
• Tang J, Sui CJ, Wang DF, et al. Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma. Theranostics. 2020;10(12):5384–5397.
   PubMed Web of Science ®Google Scholar
• Hu B, Cheng JW, Hu JW, et al. KPNA3 confers sorafenib resistance to advanced hepatocellular carcinoma via TWIST regulated epithelial-mesenchymal transition. J Cancer. 2019;10(17):3914–3925.
   PubMed Web of Science ®Google Scholar
• Lin H, Zhang R, Wu W, et al. Comprehensive network analysis of the molecular mechanisms associated with sorafenib resistance in hepatocellular carcinoma. Cancer Genet. 2020;245:27–34.
   PubMed Web of Science ®Google Scholar
• Li N, Wei L, Liu X, et al. A frizzled-like cysteine-rich domain in glypican-3 mediates Wnt binding and regulates hepatocellular carcinoma tumor growth in mice. Hepatology. 2019;70(4):1231–1245.
   PubMed Web of Science ®Google Scholar
• Lin H-H, Feng W-C, and Lu L-C, et al. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma. Cancer Lett. 2016;381(1):58–66.
   PubMed Web of Science ®Google Scholar
• Lachenmayer A, Alsinet C, Savic R, et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res. 2012;18(18):4997–5007.
   PubMed Web of Science ®Google Scholar
• Harding JJ, Nandakumar S, and Armenia J, et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res. 2019;25(7):2116–2126.
   PubMed Web of Science ®Google Scholar
• Horwitz E, Stein I, Andreozzi M, et al. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. Cancer Discov. 2014;4(6):730–743.
   PubMed Web of Science ®Google Scholar
• Llovet JM. Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma. Cancer Cell. 2014;25(5):560–562. PMID: 24823635; PMCID: PMC4071286.
   PubMed Web of Science ®Google Scholar
• Scartozzi M, Faloppi L, Svegliati Baroni G, et al. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int J Cancer. 2014;135(5):1247–1256.
   PubMed Web of Science ®Google Scholar
• Faloppi L, Puzzoni M, Casadei Gardini A, et al. Angiogenesis genotyping and clinical outcomes in patients with advanced hepatocellular carcinoma receiving sorafenib: the ALICE-2 study. Target Oncol. 2020;15(1):115–126. Erratum in: Target Oncol. 2020c15(6):801-802.
   PubMed Web of Science ®Google Scholar
• Gardini AC, Faloppi L, Aprile G, et al. Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. Tumori. 2018;104(6):476–479.
   PubMed Web of Science ®Google Scholar
• Ghafouri-Fard S, Shoorei H, Abak A, et al. Role of non-coding RNAs in modulating the response of cancer cells to paclitaxel treatment. Biomed Pharmacother. 2021;134:111172.
   PubMed Web of Science ®Google Scholar
• Wei L, Wang X, Lv L, et al. The emerging role of noncoding RNAs in colorectal cancer chemoresistance. Cell Oncol (Dordr). 2019;42(6):757–768.
   PubMed Web of Science ®Google Scholar
• Li J, Zhao J, Wang H, et al. MicroRNA-140-3p enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by targeting pregnenolone X receptor. Onco Targets Ther. 2018;11:5885–5894.
   PubMed Web of Science ®Google Scholar
• Shao QP, Wei C, Yang J, et al. miR-3609 decelerates the clearance of sorafenib in hepatocellular carcinoma cells by targeting EPAS-1 and reducing the activation of the pregnane X receptor pathway. Onco Targets Ther. 2020;13:7213–7227.
   PubMed Web of Science ®Google Scholar
• Li B, Feng F, Jia H, et al. Rhamnetin decelerates the elimination and enhances the antitumor effect of the molecular-targeting agent sorafenib in hepatocellular carcinoma cells via the miR-148a/PXR axis. Food Funct. 2021;12(6):2404–2417.
   PubMed Web of Science ®Google Scholar
• Tan W, Lin Z, Chen X, et al. miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1. Ann Transl Med. 2021;9(1):38.
   PubMed Web of Science ®Google Scholar
• He C, Dong X, Zhai B, et al. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. Oncotarget. 2015;6(30):28867–28881.
   PubMedGoogle Scholar
• Li W, Dong X, and He C, et al. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. J Exp Clin Cancer Res. 2019;38(1):183.
   PubMedGoogle Scholar
• Zhou Y, Huang Y, and Dai T, et al. LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1. Biomed Pharmacother. 2021;133:111030.
   PubMed Web of Science ®Google Scholar
• Sui C, Dong Z, and Yang C, et al. LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma. J Cell Mol Med. 2019;23(9):6024–6033.
   PubMed Web of Science ®Google Scholar
• Fan L, Huang X, Chen J, et al. Long noncoding RNA MALAT1 contributes to sorafenib resistance by targeting miR-140-5p/Aurora-A signaling in hepatocellular carcinoma. Mol Cancer Ther. 2020;19(5):1197–1209.
   PubMed Web of Science ®Google Scholar
• Zhang PF, Wang F, Wu J, et al. LncRNA SNHG3 induces EMT and sorafenib resistance by modulating the miR-128/CD151 pathway in hepatocellular carcinoma. J Cell Physiol. 2019;234(3):2788–2794.
   PubMed Web of Science ®Google Scholar
• Ogasawara S, Mihara Y, Kondo R, et al. Antiproliferative effect of lenvatinib on human liver cancer cell lines in vitro and in vivo. Anticancer Res. 2019;39(11):5973–5982.
   PubMed Web of Science ®Google Scholar
• Chuma M, Uojima H, Numata K, et al. Early changes in circulating FGF19 and Ang-2 levels as possible predictive biomarkers of clinical response to lenvatinib therapy in hepatocellular carcinoma. Cancers (Basel). 2020;12(2):293.
   PubMed Web of Science ®Google Scholar
• Hoshi T, Watanabe Miyano S, Watanabe H, et al. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades. Biochem Biophys Res Commun. 2019;513(1):1–7.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Song J, Zhang D, et al. Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib. Life Sci. 2021;264:118642.
   PubMed Web of Science ®Google Scholar
• Takagi H, Kaji K, Nishimura N, et al. The angiotensin II receptor blocker losartan sensitizes human liver cancer cells to lenvatinib-mediated cytostatic and angiostatic effects. Cells. 2021;10(3):575.
   PubMed Web of Science ®Google Scholar
• Zheng A, Chevalier N, Calderoni M, et al. CRISPR/Cas9 genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib, and regorafenib sensitivity gene in hepatocellular carcinoma. Oncotarget. 2019;10(66):7058–7070.
   PubMedGoogle Scholar
• Arechederra M, Bazai SK, Abdouni A, et al. ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma. J Hepatol. 2021;74(4):893–906.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Dumas J, and Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245–255.
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66.
   PubMed Web of Science ®Google Scholar
• Granito A, Forgione A, Marinelli S, et al. Experience with regorafenib in the treatment of hepatocellular carcinoma. Therap Adv Gastroenterol. 2021;14:17562848211016959.
   Web of Science ®Google Scholar
• Granito A, Marinelli S, and Forgione A, et al. Regorafenib combined with other systemic therapies: exploring promising therapeutic combinations in HCC. J Hepatocell Carcinoma. 2021;8:477–492.
   PubMed Web of Science ®Google Scholar
• Teufel M, Seidel H, Köchert K, et al. Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma. Gastroenterology. 2019;156(6):1731–1741.
   PubMed Web of Science ®Google Scholar
• Solms A, Reinecke I, and Fiala-Buskies S, et al. Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma. Eur J Pharm Sci. 2017;109S:S149-S153.
   Google Scholar
• Yukimoto A, Hirooka M, Hiraoka A, et al. Using ALBI score at the start of sorafenib treatment to predict regorafenib candidates in patients with hepatocellular carcinoma. Jpn J Clin Oncol. 2019;49(1):42–47.
   PubMed Web of Science ®Google Scholar
• Tong M, Fung TM, Luk ST, et al. ANXA3/JNK signaling promotes self-renewal and tumor growth, and its blockade provides a therapeutic target for hepatocellular carcinoma. Stem Cell Rep. 2015;5(1):45–59.
   PubMed Web of Science ®Google Scholar
• Tong M, Che N, Zhou L, et al. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib. J Hepatol. 2018;69(4):826–839.
   PubMed Web of Science ®Google Scholar
• Chu YW, Chien CH, Sung MI, et al. dBMHCC: a comprehensive hepatocelluar carcinoma (HCC) biomarker database provides a reliable prediction system for novel HCC phosphorylated biomarkers. PLoS One. 2020;15(6):e0234084.
   PubMed Web of Science ®Google Scholar
• Xiang Q, Chen W, Ren M, et al. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clin Cancer Res. 2014;20(11): 2959–2570.
   Web of Science ®Google Scholar
• Kelley RK, Verslype C, Cohn AL, et al. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Ann Oncol. 2017;28(3):528–534.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63.
   PubMed Web of Science ®Google Scholar
• Kim RD, Sarker D, Meyer T, et al. First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. Cancer Discov. 2019;9(12):1696–1707.
   PubMed Web of Science ®Google Scholar
• Chau I, Peck-Radosavljevic BC, Malfertheiner P, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: patient-focused outcome results from the randomised phase III REACH study. Eur J Cancer. 2018;100:135–136.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kang YK, Yen CJ, et al. REACH-2 study investigators. ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–296.
   PubMed Web of Science ®Google Scholar
• Kudo M, Galle PR, and Brandi G, et al. Effect of ramucirumab on ALBI grade in patients with advanced HCC: results from REACH and REACH-2. JHEP Reports. 2020;3(2):100215.
   PubMedGoogle Scholar
• Sonbol MB, Riaz IB, Naqvi SAA, et al. Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. JAMA Oncol. 2020;22(12):e204930.
   Google Scholar
• Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013;14(1):55–63.
   PubMed Web of Science ®Google Scholar
• Rimassa L, Assenat E, Peck-Radosavljevic M, et al. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 2018;19(5):682–693.
   PubMed Web of Science ®Google Scholar
• Volinsky N, Kholodenko BN. Complexity of receptor tyrosine kinase signal processing. Cold Spring Harb Perspect Biol. 2013;5(8):a009043.
   PubMed Web of Science ®Google Scholar
• Rivadeneira DB, Mayhew CN, Thangavel C, et al. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology. 2010;138(5):1920–1930.
   PubMed Web of Science ®Google Scholar
• Zhang J, Xu K, Liu P, et al. Inhibition of Rb phosphorylation leads to mTORC2-mediated activation of Akt. Mol Cell. 2016;62(6):929–942.
   PubMed Web of Science ®Google Scholar
• Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–2884.
   PubMed Web of Science ®Google Scholar
• Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904–915.
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936.
   PubMed Web of Science ®Google Scholar
• Shen J, Hu J, and Wu J, et al. Molecular characterization of long-term survivors of hepatocellular carcinoma. Aging (Albany NY). 2021;13(5):7517–7537.
   PubMedGoogle Scholar
• Reiter FP, Denk G, Ziesch A, et al. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells. Cell Oncol (Dordr). 2019;42(5):705–715.
   PubMed Web of Science ®Google Scholar
• Prawira A, Le TBU, Vu TC, et al. Ribociclib enhances infigratinib-induced cancer cell differentiation and delays resistance in FGFR-driven hepatocellular carcinoma. Liver Int. 2021;41(3):608–620.
   PubMed Web of Science ®Google Scholar
• Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3(11):1427–1438.
   PubMed Web of Science ®Google Scholar
• Dean JL, McClendon AK, Hickey TE, et al. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle. 2012;11(14):2756–2761.
   PubMed Web of Science ®Google Scholar
• Digiacomo G, Fumarola C, La Monica S, et al. Simultaneous combination of the CDK4/6 inhibitor palbociclib with regorafenib induces enhanced anti-tumor effects in hepatocarcinoma cell lines. Front Oncol. 2020;10:563249.
   PubMed Web of Science ®Google Scholar
• Hsieh FS, Chen YL, Hung MH, et al. Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner. Mol Oncol. 2017;11(8):1035–1049.
   PubMed Web of Science ®Google Scholar
• Ceballos MP, Angel A, Delprato CB, et al. Sirtuin 1 and 2 inhibitors enhance the inhibitory effect of sorafenib in hepatocellular carcinoma cells. Eur J Pharmacol. 2021;892:173736.
   PubMed Web of Science ®Google Scholar
• Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29–39.
   PubMed Web of Science ®Google Scholar
• Zhang P, Yang L, Li Y. Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies. Am J Cancer Res. 2019;9(8):1536–1545.
   PubMed Web of Science ®Google Scholar
• Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8(5):765–772.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–1034.
   PubMed Web of Science ®Google Scholar
• Dai X, Pi G, Yang SL, et al. Association of PD-L1 and HIF-1α coexpression with poor prognosis in hepatocellular carcinoma. Transl Oncol. 2018;11(2):559–566.
   PubMed Web of Science ®Google Scholar
• Xu H, Liang XL, Liu XG, et al. The landscape of PD-L1 expression and somatic mutations in hepatocellular carcinoma. J Gastrointest Oncol. 2021;12(3):1132–1140.
   PubMed Web of Science ®Google Scholar
• Shrestha R, Prithviraj P, Anaka M, et al. Monitoring immune checkpoint regulators as predictive biomarkers in hepatocellular carcinoma. Front Oncol. 2018;8:269.
   PubMed Web of Science ®Google Scholar
• Chang B, Huang T, Wei H, et al. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma. Cancer Immunol Immunother. 2019;68(3):353–363.
   PubMed Web of Science ®Google Scholar
• Chikuma SCTLA-4. an essential immune-checkpoint for T-cell activation. Curr Top Microbiol Immunol. 2017;410:99–126.
   PubMed Web of Science ®Google Scholar
• Kalathil S, Lugade AA, Miller A, et al. Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res. 2013;73(8):2435–2444.
   PubMed Web of Science ®Google Scholar
• Granito A, Muratori L, and Lalanne C, et al. Hepatocellular carcinoma in viral and autoimmune liver diseases: role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World J Gastroenterol. 2021;27(22):2994–3009.
   PubMed Web of Science ®Google Scholar
• Kalathil SG, Lugade AA, Miller A, et al. PD-1+ and Foxp3+ T cell reduction correlates with survival of HCC patients after sorafenib therapy. JCI Insight. 2016;1(11):e86182.
   PubMed Web of Science ®Google Scholar
• Lai SC, Su YT, Chi CC, et al. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation. J Exp Clin Cancer Res. 2019;38(1):474.
   PubMed Web of Science ®Google Scholar
• Liu J, Liu Y, Meng L, et al. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. Oncol Rep. 2017;38:899–907.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhao X, Ma X, et al. KCNQ1OT1 contributes to sorafenib resistance and programmed death-ligand-1-mediated immune escape via sponging miR-506 in hepatocellular carcinoma cells. Int J Mol Med. 2020;46(5):1794–1804.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502.
   PubMed Web of Science ®Google Scholar
• Kudo M, Matilla A, and Santoro A, et al. CheckMate 040 cohort 5: a phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol. 2021;75(3):600–609. .
   PubMed Web of Science ®Google Scholar
• Sangro B, Melero I, Wadhawan S, et al. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J Hepatol. 2020;73(6):1460–1469.
   PubMed Web of Science ®Google Scholar
• Yau T, Kang YK, Kim TY, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 2020;6(11):e204564.
   PubMed Web of Science ®Google Scholar
• Saung MT, Pelosof L, Casak S, et al. FDA approval summary: nivolumab plus ipilimumab for the treatment of patients with hepatocellular carcinoma previously treated with sorafenib. Oncologist. 2021;26(9):797–806.
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Cortellini A, Sukumaran A, et al. PRIME-HCC: phase ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma. BMC Cancer. 2021;21(1):301.
   PubMed Web of Science ®Google Scholar
• Yau T, Park JW, Finn RS, et al. LBA38_PR - checkMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019;30(Suppl.5):v874–v875.
   Google Scholar
• Finn RS, Ryoo BY, Merle P, et al. KEYNOTE-240 investigators. pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38(3):193–202.
   PubMed Web of Science ®Google Scholar
• Scheiner B, Kirstein MM, Hucke F, et al. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. Aliment Pharmacol Ther. 2019;49(10):1323–1333.
   PubMed Web of Science ®Google Scholar
• Deng H, Kan A, Lyu N, et al. Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell death-1 checkpoint blockade in hepatocellular carcinoma. Liver Cancer. 2020;9(3):338–357.
   PubMed Web of Science ®Google Scholar
• Feun LG, Li YY, and Wu C, et al. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma. Cancer. 2019;125(20):3603–3614.
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413.
   PubMed Web of Science ®Google Scholar
• DeLeon TT, Ahn DH, Bogenberger JM, et al. Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. Future Oncol. 2018;14(6):553–566.
   PubMed Web of Science ®Google Scholar
• Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59(1):81–88.
   PubMed Web of Science ®Google Scholar
• Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66(3):545–551.
   PubMed Web of Science ®Google Scholar
• Agdashian D, ElGindi M, Xie C, et al. The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. Cancer Immunol Immunother. 2019;68(4):599–608.
   PubMed Web of Science ®Google Scholar
• Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44–56.
   PubMed Web of Science ®Google Scholar
• Liu Z, Jiao D, Liu L, et al. Development and validation of a robust immune-related risk signature for hepatocellular carcinoma. Medicine (Baltimore). 2021;100(10):e24683.
   PubMed Web of Science ®Google Scholar
• Ou Q, Yu Y, Li A, et al. Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma. Ann Transl Med. 2020;8(5):230.
   PubMed Web of Science ®Google Scholar